Get the Stockscreener App
6.10
2.52%
0.15
After Hours:
6.16
0.06
+0.98%
Amicus Therapeutics Inc stock is traded at $6.10, with a volume of 3.12M.
It is up +2.52% in the last 24 hours and down -2.56% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$5.95
Open:
$6.01
24h Volume:
3.12M
Relative Volume:
0.71
Market Cap:
$1.88B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-17.94
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
+7.21%
1M Performance:
-2.56%
6M Performance:
-35.18%
1Y Performance:
-37.82%
1-Day Range:
$5.97
$6.15
1-Week Range:
$5.645
$6.15
52-Week Range:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.10 | 1.88B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Turn A Profit? - simplywall.st
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week LowTime to Sell? - MarketBeat
Amicus Therapeutics stock hits 52-week low at 5.79 USD By Investing.com - Investing.com Canada
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.22 Average Price Target from Analysts - MarketBeat
(FOLD) Technical Data - news.stocktradersdaily.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Wedge Capital Management L L P NC - MarketBeat
Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma (NASDAQ:FOLD) - Seeking Alpha
Amicus Therapeutics at Goldman Sachs Conference: Strategic Insights Unveiled By Investing.com - Investing.com Canada
Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - Yahoo Finance
Zacks Research Issues Pessimistic Outlook for FOLD Earnings - MarketBeat
Two Sigma Investments LP Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Therapeutic Market Deep Research Report with - openPR.com
Millennium Management LLC Buys 44,449 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda - GuruFocus
New Strong Sell Stocks for June 3rd - Yahoo Finance
Amicus (FOLD) Reports Positive Findings from PROPEL Study in Pompe Disease | FOLD Stock News - GuruFocus
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve - GlobeNewswire
Clinical Data Reveals Treatment Advantages: 77% of Pompe Disease Patients Show Improvement with New Therapy - Stock Titan
Two Sigma Advisers LP Acquires 52,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Cetera Investment Advisers Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
How to Take Advantage of moves in (FOLD) - news.stocktradersdaily.com
Man Group plc Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 | FOLD Stock News - GuruFocus
Rare Disease Leader Amicus Therapeutics to Present Latest Updates at Major Healthcare Conferences - Stock Titan
Millennium Management LLC Has $4.31 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Voloridge Investment Management LLC Sells 397,497 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Squarepoint Ops LLC Purchases 753,060 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Neo Ivy Capital Management Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Woodline Partners LP Sells 726,952 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Ameriprise Financial Inc. - Defense World
Pompe Disease Market: Epidemiology, Therapies, Companies, - openPR.com
Teza Capital Management LLC Sells 68,066 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Nuveen Asset Management LLC Purchases 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
297,830 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Sovereign s Capital Management LLC - MarketBeat
Vestal Point Capital LP Acquires New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Deutsche Bank AG Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Rafferty Asset Management LLC Sells 73,883 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amicus Therapeutics Inc Stock (FOLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Campbell Bradley L | President and CEO |
Feb 19 '25 |
Sale |
10.00 |
400 |
4,000 |
1,150,657 |
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):